KZIANasdaqPharmaceutical PreparationsFiscal year ends June 30

KAZIA THERAPEUTICS LTD

Financials through fiscal 2025, year ended Jun 30, 2025Last filing: 20-F on Nov 7, 2025

$7.85+0.60 (+8.28%)

Close on Oct 19, 2026

Margins

Share of revenue, fiscal years 2015 to 2025

-49290.5%

Per year	1 year	3 years	5 years	10 years	Five-year pace
Revenue	-98.2%	–	–	–

10 fiscal years. Hover a measure to see how it is calculated.

Measure	FY2016	FY2020	FY2025
Return on equity	–	-88.0%	226.0%
Return on assets	–	-56.4%	-149.8%
Current ratio	–	2.10	0.35
Capex to revenue	128.6%	–	–
Diluted shares	427M	73M	548M

Return on equity split into margin, efficiency and leverage

Net margin-49290.5%

Asset turnover0.00×

Equity multiplier-1.51×

Return on equity, FY2025226.0%

Fiscal year	Net margin	Asset turnover	Equity multiplier	Return on equity
FY2025	-49290.5%	0.00×	-1.51×	226.0%
FY2024	-1160.2%	0.09×	24.43×	-2634.3%
FY2021	-55.5%	0.38×	1.54×	-32.4%
FY2018	-5074.8%	0.00×	1.44×	-27.1%

Parsed from the XBRL in Kazia Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-5 reverse split on Apr 17, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is KZIA.

Revenue growth-98.2% · median -72.8%

Net margin-49290.5% · median -467453.1%

Advertisement
300 × 250